Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Overview

USA - NYSE:ANRO - US02157Q1094 - Common Stock

3.94 USD
+0.34 (+9.44%)
Last: 9/22/2025, 3:50:51 PM

ANRO Key Statistics, Chart & Performance

Key Statistics
52 Week High15.04
52 Week Low1.6
Market Cap106.70M
Shares27.08M
Float24.80M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.39
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/amc
IPO02-02 2024-02-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ANRO short term performance overview.The bars show the price performance of ANRO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

ANRO long term performance overview.The bars show the price performance of ANRO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ANRO is 3.94 USD. In the past month the price increased by 0.28%. In the past year, price decreased by -73.7%.

ALTO NEUROSCIENCE INC / ANRO Daily stock chart

ANRO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 46.75 714.52B
JNJ JOHNSON & JOHNSON 17.42 419.61B
NVO NOVO-NORDISK A/S-SPONS ADR 15.27 266.61B
AZN ASTRAZENECA PLC-SPONS ADR 17.51 241.00B
NVS NOVARTIS AG-SPONSORED ADR 13.96 239.21B
MRK MERCK & CO. INC. 10.46 201.08B
PFE PFIZER INC 7.1 136.85B
SNY SANOFI-ADR 10.58 114.84B
BMY BRISTOL-MYERS SQUIBB CO 6.69 91.67B
GSK GSK PLC-SPON ADR 9.06 82.47B
ZTS ZOETIS INC 23.29 64.19B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.81 47.45B

About ANRO

Company Profile

ANRO logo image Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

Company Info

ALTO NEUROSCIENCE INC

650 Castro Street, Suite 450

Mountain View CALIFORNIA US

Employees: 76

ANRO Company Website

ANRO Investor Relations

Phone: 17732555012

ALTO NEUROSCIENCE INC / ANRO FAQ

What is the stock price of ALTO NEUROSCIENCE INC today?

The current stock price of ANRO is 3.94 USD. The price increased by 9.44% in the last trading session.


What is the ticker symbol for ALTO NEUROSCIENCE INC stock?

The exchange symbol of ALTO NEUROSCIENCE INC is ANRO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is ANRO stock listed?

ANRO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for ALTO NEUROSCIENCE INC stock?

14 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 167.51% is expected in the next year compared to the current price of 3.94. Check the ALTO NEUROSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALTO NEUROSCIENCE INC worth?

ALTO NEUROSCIENCE INC (ANRO) has a market capitalization of 106.70M USD. This makes ANRO a Micro Cap stock.


How many employees does ALTO NEUROSCIENCE INC have?

ALTO NEUROSCIENCE INC (ANRO) currently has 76 employees.


What are the support and resistance levels for ALTO NEUROSCIENCE INC (ANRO) stock?

ALTO NEUROSCIENCE INC (ANRO) has a support level at 3.5 and a resistance level at 3.91. Check the full technical report for a detailed analysis of ANRO support and resistance levels.


Should I buy ALTO NEUROSCIENCE INC (ANRO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALTO NEUROSCIENCE INC (ANRO) stock pay dividends?

ANRO does not pay a dividend.


When does ALTO NEUROSCIENCE INC (ANRO) report earnings?

ALTO NEUROSCIENCE INC (ANRO) will report earnings on 2025-11-12, after the market close.


What is the Price/Earnings (PE) ratio of ALTO NEUROSCIENCE INC (ANRO)?

ALTO NEUROSCIENCE INC (ANRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).


What is the Short Interest ratio of ALTO NEUROSCIENCE INC (ANRO) stock?

The outstanding short interest for ALTO NEUROSCIENCE INC (ANRO) is 6.86% of its float. Check the ownership tab for more information on the ANRO short interest.


ANRO Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ANRO. When comparing the yearly performance of all stocks, ANRO is a bad performer in the overall market: 81.02% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ANRO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ANRO. The financial health of ANRO is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANRO Financial Highlights

Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 13.41% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -41.08%
ROE -52.55%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%-8.33%
Sales Q2Q%N/A
EPS 1Y (TTM)13.41%
Revenue 1Y (TTM)N/A

ANRO Forecast & Estimates

14 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 167.51% is expected in the next year compared to the current price of 3.94.


Analysts
Analysts85.71
Price Target10.54 (167.51%)
EPS Next Y-3.78%
Revenue Next YearN/A

ANRO Ownership

Ownership
Inst Owners77.46%
Ins Owners7.48%
Short Float %6.86%
Short Ratio16.77